WikiStock

世界会社ライセンス検索App

English
ダウンロード
トップページ-ニュース-

<Research>G Sachs Trims TPs on Medicals Broadly; Investors Still Eye on Anti-corruption Impact

iconAASTOCKS

2024-07-19 11:32

Goldman Sachs released a report. Ahead of the 2Q24 and 1H24 results season, the TPs on the whole line of health care related stocks were cut, with the...

  Goldman Sachs released a report. Ahead of the 2Q24 and 1H24 results season, the TPs on the whole line of health care related stocks were cut, with the average range of about 9%. The broker also lowered its industry sales estimates for FY2024-25 by 1%-15% and 1%-16%. The broker believed that investors will remain centered on the impact of from anti-corruption, roll-out of the central procurement policies and potential stimulus from trade-in program.

  Goldman Sachs' ratings and TPs for pharmaceuticals are listed below:

  Related NewsNomura Chops HYGEIA HEALTH (06078.HK) TP to $50.7, Cuts Rev./ Earnings Forecasts

  Stocks | Ratings| Target Prices

  WEIGAO GROUP (01066.HK) -0.180 (-4.276%) Short selling $5.80M; Ratio 17.469% | Buy | $8.7 -> $7.8

  KANGJI MEDICAL (09997.HK) -0.050 (-0.893%) Short selling $150.37K; Ratio 20.905% | Buy | $11.2 -> $10.6

  Related NewsM Stanley Expects Medtechs to Report Weak 2Q24 Results; TPs Adjusted

  AK MEDICAL (01789.HK) -0.060 (-1.304%) Short selling $218.38K; Ratio 15.168% | Buy | $8.9 -> $8.2

  HYGEIA HEALTH (06078.HK) -1.100 (-3.971%) Short selling $5.07M; Ratio 29.449% | Buy | $50 -> $46

  HEARTCARE-B (06609.HK) -0.080 (-0.485%) | Buy | $29.8 -> $25.6

  GUSHENGTANG (02273.HK) -0.350 (-0.927%) Short selling $1.33M; Ratio 16.594% | Buy | $61 -> $60

  MICROTECH MED-B (02235.HK) -0.110 (-2.933%) | Sell | $5.7 -> $5

  JXR (01951.HK) -0.200 (-6.873%) Short selling $15.12M; Ratio 29.856% | Neutral | $3.39 -> $3.2

  VENUS MEDTECH-B (02500.HK) 0.000 (0.000%) | Neutral | $6 -> $5.6

  (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-19 12:25.)

  AAStocks Financial News

免責事項:このコンテンツの見解は筆者個人的な見解を示すものに過ぎず、当社の投資アドバイスではありません。当サイトは、記事情報の正確性、完全性、適時性を保証するものではなく、情報の使用または関連コンテンツにより生じた、いかなる損失に対しても責任は負いません。